Temporal muscle thickness as a prognostic marker in newly diagnosed glioblastoma patients: translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials
Clin Cancer Res. 2021 Oct 19:clincanres.1987.2021. doi: 10.1158/1078-0432.CCR-21-1987. Online ahead of print.ABSTRACTPURPOSE: To investigate the prognostic relevance of temporal muscle thickness (TMT) as a surrogate parameter of skeletal muscle status in patients with newly diagnosed glioblastoma.METHODS: We assessed TMT in cranial magnetic resonance images (MRI) of 755 patients enrolled in the CENTRIC EORTC 26071-22072 study (n=508) and CORE study (n=247). We used predefined sex-specific TMT cutoff values to categorize "patients at risk of sarcopenia" and "patients with normal muscle status" at baselin...
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Julia Furtner Michael Weller Michael Weber Thierry Gorlia Burt Nabors David A Reardon Joerg-Christian Tonn Roger Stupp Matthias Preusser Source Type: research

Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial
CONCLUSIONS: Luminal B-like BCs with a Basal molecular subtype and/or a state of immune activation may respond to sequential anthracyclines and anti-PD-1. Our data generate hypotheses that, if validated, could guide immunotherapy development in this context.PMID:34667023 | DOI:10.1158/1078-0432.CCR-21-2260 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Maria Vittoria Dieci Valentina Guarneri Anna Tosi Giancarlo Bisagni Antonino Musolino Simon Spazzapan Gabriella Moretti Grazia Maria Vernaci Gaia Griguolo Tommaso Giarratano Loredana Urso Francesca Schiavi Claudia Pinato Giovanna Magni Marcello Lo Mele Gi Source Type: research

A High-Content Screen for C/EBP α Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
CONCLUSIONS: This high-content screen revealed potential treatments for DDLS. These include irinotecan, which induces apoptosis of DDLS cells in a C/EBPα-dependent, p53-independent manner and should be clinically evaluated in patients with advanced DDLS.PMID:34667024 | DOI:10.1158/1078-0432.CCR-19-2486 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Christina V Angeles Ana Velez-Rosborough Jordan Rios Bernadette Laxa David Shum Penelope D Ruiz Yawei Shen Irina Ostrovnaya Rodrigo Gularte M érida Benjamin A Nacev Mark A Dickson Hakim Djaballah Tomoyo Okada Samuel Singer Source Type: research

Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck
CONCLUSIONS: (Neo)adjuvant N+L was well tolerated with a 43% pathologic response rate. We observed favorable DFS and excellent 2-year OS among high-risk, previously treated patients exhibiting a pathologic response. Further evaluation of this strategy is warranted.PMID:34667025 | DOI:10.1158/1078-0432.CCR-21-2635 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Glenn J Hanna Anne ONeill Kee-Young Shin Kristine Wong Vickie Y Jo Charles T Quinn Jennifer M Cutler Michelle Flynn Patrick H Lizotte Donald J Annino Laura A Goguen Jason I Kass Eleni M Rettig Rosh K V Sethi Jochen H Lorch Jonathan D Schoenfeld Danielle N Source Type: research

Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
CONCLUSIONS: Tumor genomics differed by race even after accounting for clinical characteristics. Equalizing access to care may not fully eliminate such differences. Therapies for alterations more common in racial minorities are needed. Tumor genomic differences should not be assumed to be entirely due to germline genetics.PMID:34667026 | DOI:10.1158/1078-0432.CCR-21-2577 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Konrad H Stopsack Subhiksha Nandakumar Kanika Arora Bastien Nguyen Samantha E Vasselman Barbara Nweji Sean M McBride Michael J Morris Dana E Rathkopf Susan F Slovin Daniel C Danila Karen A Autio Howard I Scher Lorelei A Mucci David B Solit Mithat Gonen Yu Source Type: research

Real-world Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020
This study aimed to analyze attributes of real-world studies in FDA's decision-making and characteristics of full versus accelerated approvals through a systematic review of oncology product approvals. Oncology approvals from 2015-2020 were reviewed from FDA.gov. Applications were screened for inclusion of RWE, and variables related to regulatory designations of the application, pivotal clinical trial, and real-world studies were extracted. FDA feedback was reviewed to identify takeaways and best practices for adequate RWE. Among 133 original and 573 supplemental approvals for oncology, 11 and 2, respectively, included RWE...
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Bhakti Arondekar Mei Sheng Duh Rachel H Bhak Maral DerSarkissian Lynn Huynh Kelsey Wang John Wojciehowski Melody Wu Bryon Wornson Alexander Niyazov George D Demetri Source Type: research

Morphological and genomic characteristics of breast cancers occurring in individuals with Lynch Syndrome
CONCLUSIONS: A subset of BCs developing in LS individuals are etiologically linked to MMRd and may benefit from anti-PD1/PD-L1 immunotherapy.PMID:34667028 | DOI:10.1158/1078-0432.CCR-21-2027 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Christopher J Schwartz Edaise M da Silva Antonio Marra Andrea M Gazzo Pier Selenica Vikas K Rai Diana Mandelker Fresia Pareja Maksym Misyura Timothy M D'Alfonso Edi Brogi Pamela Drullinsky Pedram Razavi Mark E Robson Joshua Z Drago Hannah Y Wen Liying Zha Source Type: research

An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission
CONCLUSIONS: MM-GVAX, along with lenalidomide, effectively primed durable immunity and resulted long-term disease control, as suggested by the reappearance of a detectable, fluctuating M-spike without meeting the criteria for clinical relapse. For patients in a nCR, MM-GVAX administration was safe and resulted in prolonged clinical responses.PMID:34667029 | DOI:10.1158/1078-0432.CCR-21-1916 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Luca Biavati Carol Ann Huff Anna Ferguson Amy Sidorski M Amanda Stevens Lakshmi Rudraraju Cristina Zucchinetti Syed Abbas Ali Philip Imus Christian B Gocke Rachel M Gittelman Sarah Johnson Catherine Sanders Marissa Vignali Anita Gandhi Xiaobu Ye Kimberly Source Type: research

Inactivation of AMPK leads to attenuation of antigen presentation and immune evasion in lung adenocarcinoma
Conclusions:The results provide evidence that the immune evasion noted in LKB1 inactivated lung cancer is due to subsequent inactivation of AMPK and attenuation of antigen presentation.PMID:34667030 | DOI:10.1158/1078-0432.CCR-21-2049 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Yajing Gao Pekka J P P äivinen Sushil Tripathi Eva Domenech-Moreno Iris Poh Ling P L Wong Kari Vaahtomeri Ashwini S Nagaraj Sarang S Talwelkar Marc Foretz Emmy W Verschuren Benoit Viollet Yan Yan Tomi P Makela Source Type: research

Temporal muscle thickness as a prognostic marker in newly diagnosed glioblastoma patients: translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials
Clin Cancer Res. 2021 Oct 19:clincanres.1987.2021. doi: 10.1158/1078-0432.CCR-21-1987. Online ahead of print.ABSTRACTPURPOSE: To investigate the prognostic relevance of temporal muscle thickness (TMT) as a surrogate parameter of skeletal muscle status in patients with newly diagnosed glioblastoma.METHODS: We assessed TMT in cranial magnetic resonance images (MRI) of 755 patients enrolled in the CENTRIC EORTC 26071-22072 study (n=508) and CORE study (n=247). We used predefined sex-specific TMT cutoff values to categorize "patients at risk of sarcopenia" and "patients with normal muscle status" at baselin...
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Julia Furtner Michael Weller Michael Weber Thierry Gorlia Burt Nabors David A Reardon Joerg-Christian Tonn Roger Stupp Matthias Preusser Source Type: research

Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial
CONCLUSIONS: Luminal B-like BCs with a Basal molecular subtype and/or a state of immune activation may respond to sequential anthracyclines and anti-PD-1. Our data generate hypotheses that, if validated, could guide immunotherapy development in this context.PMID:34667023 | DOI:10.1158/1078-0432.CCR-21-2260 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Maria Vittoria Dieci Valentina Guarneri Anna Tosi Giancarlo Bisagni Antonino Musolino Simon Spazzapan Gabriella Moretti Grazia Maria Vernaci Gaia Griguolo Tommaso Giarratano Loredana Urso Francesca Schiavi Claudia Pinato Giovanna Magni Marcello Lo Mele Gi Source Type: research

A High-Content Screen for C/EBP α Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
CONCLUSIONS: This high-content screen revealed potential treatments for DDLS. These include irinotecan, which induces apoptosis of DDLS cells in a C/EBPα-dependent, p53-independent manner and should be clinically evaluated in patients with advanced DDLS.PMID:34667024 | DOI:10.1158/1078-0432.CCR-19-2486 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Christina V Angeles Ana Velez-Rosborough Jordan Rios Bernadette Laxa David Shum Penelope D Ruiz Yawei Shen Irina Ostrovnaya Rodrigo Gularte M érida Benjamin A Nacev Mark A Dickson Hakim Djaballah Tomoyo Okada Samuel Singer Source Type: research

Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck
CONCLUSIONS: (Neo)adjuvant N+L was well tolerated with a 43% pathologic response rate. We observed favorable DFS and excellent 2-year OS among high-risk, previously treated patients exhibiting a pathologic response. Further evaluation of this strategy is warranted.PMID:34667025 | DOI:10.1158/1078-0432.CCR-21-2635 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Glenn J Hanna Anne ONeill Kee-Young Shin Kristine Wong Vickie Y Jo Charles T Quinn Jennifer M Cutler Michelle Flynn Patrick H Lizotte Donald J Annino Laura A Goguen Jason I Kass Eleni M Rettig Rosh K V Sethi Jochen H Lorch Jonathan D Schoenfeld Danielle N Source Type: research

Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
CONCLUSIONS: Tumor genomics differed by race even after accounting for clinical characteristics. Equalizing access to care may not fully eliminate such differences. Therapies for alterations more common in racial minorities are needed. Tumor genomic differences should not be assumed to be entirely due to germline genetics.PMID:34667026 | DOI:10.1158/1078-0432.CCR-21-2577 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Konrad H Stopsack Subhiksha Nandakumar Kanika Arora Bastien Nguyen Samantha E Vasselman Barbara Nweji Sean M McBride Michael J Morris Dana E Rathkopf Susan F Slovin Daniel C Danila Karen A Autio Howard I Scher Lorelei A Mucci David B Solit Mithat Gonen Yu Source Type: research

Real-world Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020
This study aimed to analyze attributes of real-world studies in FDA's decision-making and characteristics of full versus accelerated approvals through a systematic review of oncology product approvals. Oncology approvals from 2015-2020 were reviewed from FDA.gov. Applications were screened for inclusion of RWE, and variables related to regulatory designations of the application, pivotal clinical trial, and real-world studies were extracted. FDA feedback was reviewed to identify takeaways and best practices for adequate RWE. Among 133 original and 573 supplemental approvals for oncology, 11 and 2, respectively, included RWE...
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Bhakti Arondekar Mei Sheng Duh Rachel H Bhak Maral DerSarkissian Lynn Huynh Kelsey Wang John Wojciehowski Melody Wu Bryon Wornson Alexander Niyazov George D Demetri Source Type: research

Morphological and genomic characteristics of breast cancers occurring in individuals with Lynch Syndrome
CONCLUSIONS: A subset of BCs developing in LS individuals are etiologically linked to MMRd and may benefit from anti-PD1/PD-L1 immunotherapy.PMID:34667028 | DOI:10.1158/1078-0432.CCR-21-2027 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Christopher J Schwartz Edaise M da Silva Antonio Marra Andrea M Gazzo Pier Selenica Vikas K Rai Diana Mandelker Fresia Pareja Maksym Misyura Timothy M D'Alfonso Edi Brogi Pamela Drullinsky Pedram Razavi Mark E Robson Joshua Z Drago Hannah Y Wen Liying Zha Source Type: research

An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission
CONCLUSIONS: MM-GVAX, along with lenalidomide, effectively primed durable immunity and resulted long-term disease control, as suggested by the reappearance of a detectable, fluctuating M-spike without meeting the criteria for clinical relapse. For patients in a nCR, MM-GVAX administration was safe and resulted in prolonged clinical responses.PMID:34667029 | DOI:10.1158/1078-0432.CCR-21-1916 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Luca Biavati Carol Ann Huff Anna Ferguson Amy Sidorski M Amanda Stevens Lakshmi Rudraraju Cristina Zucchinetti Syed Abbas Ali Philip Imus Christian B Gocke Rachel M Gittelman Sarah Johnson Catherine Sanders Marissa Vignali Anita Gandhi Xiaobu Ye Kimberly Source Type: research

Inactivation of AMPK leads to attenuation of antigen presentation and immune evasion in lung adenocarcinoma
Conclusions:The results provide evidence that the immune evasion noted in LKB1 inactivated lung cancer is due to subsequent inactivation of AMPK and attenuation of antigen presentation.PMID:34667030 | DOI:10.1158/1078-0432.CCR-21-2049 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Yajing Gao Pekka J P P äivinen Sushil Tripathi Eva Domenech-Moreno Iris Poh Ling P L Wong Kari Vaahtomeri Ashwini S Nagaraj Sarang S Talwelkar Marc Foretz Emmy W Verschuren Benoit Viollet Yan Yan Tomi P Makela Source Type: research

Selected Articles from This Issue
Clin Cancer Res. 2021 Oct 15;27(20):5441. doi: 10.1158/1078-0432.CCR-27-20-HI.NO ABSTRACTPMID:34654738 | DOI:10.1158/1078-0432.CCR-27-20-HI (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 16, 2021 Category: Cancer & Oncology Source Type: research

Selected Articles from This Issue
Clin Cancer Res. 2021 Oct 15;27(20):5441. doi: 10.1158/1078-0432.CCR-27-20-HI.NO ABSTRACTPMID:34654738 | DOI:10.1158/1078-0432.CCR-27-20-HI (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 16, 2021 Category: Cancer & Oncology Source Type: research

Selected Articles from This Issue
Clin Cancer Res. 2021 Oct 15;27(20):5441. doi: 10.1158/1078-0432.CCR-27-20-HI.NO ABSTRACTPMID:34654738 | DOI:10.1158/1078-0432.CCR-27-20-HI (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 16, 2021 Category: Cancer & Oncology Source Type: research

Selected Articles from This Issue
Clin Cancer Res. 2021 Oct 15;27(20):5441. doi: 10.1158/1078-0432.CCR-27-20-HI.NO ABSTRACTPMID:34654738 | DOI:10.1158/1078-0432.CCR-27-20-HI (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 16, 2021 Category: Cancer & Oncology Source Type: research

< em > AACR Cancer Progress Report 2021 < /em > : Discovery Science Driving Clinical Breakthroughs
Clin Cancer Res. 2021 Oct 13. doi: 10.1158/1078-0432.CCR-21-3367. Online ahead of print.NO ABSTRACTPMID:34645645 | DOI:10.1158/1078-0432.CCR-21-3367 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Rajarshi Sengupta Sayyed Kaleem Zaidi Source Type: research

Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer
Clin Cancer Res. 2021 Oct 13:clincanres.1650.2021. doi: 10.1158/1078-0432.CCR-21-1650. Online ahead of print.ABSTRACTPURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with RAS wild-type (RASwt), metastatic colorectal adenocarcinoma (mCRC).EXPERIMENTAL DESIGN: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with {greater than or equal to} one prior line of therapy for advanced disease. We analyzed baseline on-treatment tumor tissues for changes in the tumor microenvironment (TME), using flow cytometry and multispectral imm...
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Christos Fountzilas David L Bajor Sarbajit Mukherjee Joel Saltzman Agnieszka K Witkiewicz Orla Maguire Hans Minderman Ram Nambiar Hanna R Rosenheck Erik S Knudsen Jason B Muhitch Scott I Abrams Chong Wang Alan D Hutson Kristopher Attwood Karen A Hicks Jen Source Type: research

Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer
Conclusion: Our data demonstrate that an oHSV encoding a full-length human IgG1 anti-CD47 mAb, when used as a single agent or combined with another agent, is a promising approach for improving ovarian cancer treatment via enhancing innate immunity, as well as performing its known oncolytic function and modulation of immune cells.PMID:34645647 | DOI:10.1158/1078-0432.CCR-21-1248 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Lei Tian Bo Xu Kun-Yu Teng Mihae Song Zheng Zhu Yuqing Chen Jing Wang Jianying Zhang Mingye Feng Balveen Kaur Lorna Rodriguez-Rodriguez Michael A Caligiuri Jianhua Yu Source Type: research

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study
Conclusions: Adavosertib showed preliminary efficacy when combined with chemotherapy. The most promising treatment combination was adavosertib 225 mg twice daily on days 1-3, 8-10, and 15-17 plus carboplatin every 21 days. However, hematologic toxicity was more frequent than would be expected for carboplatin monotherapy, and the combination requires further study to optimize the dose, schedule, and supportive medications.PMID:34645648 | DOI:10.1158/1078-0432.CCR-21-0158 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Kathleen N Moore Setsuko K Chambers Erika P Hamilton Lee-May Chen Amit M Oza Sharad A Ghamande Gottfried E Konecny Steven C Plaxe Daniel L Spitz Jill J J Geenen Tiffany A Troso-Sandoval Janiel M Cragun Esteban Rodrigo Imedio Sanjeev Kumar Ganesh M Mugundu Source Type: research

Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer
Clin Cancer Res. 2021 Oct 13:clincanres.1628.2021. doi: 10.1158/1078-0432.CCR-21-1628. Online ahead of print.ABSTRACTPurpose: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2- breast cancer; (ii) the pharmacodynamic effect of the agents on the biomarkers. Experimental design: 307 postmenopausal women with ER+/HER2- primary breast cancer were randomly assigned to neoadjuvant treatment with letrozole for 14 weeks; letrozole for 2 weeks, then letrozole+palbociclib to 14 weeks; palbociclib for 2 weeks, then letroz...
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Mitch Dowsett Lucy Kilburn Mothaffar F Rimawi C Kent Osborne Katherine Pogue-Geile Yuan Liu Samuel A Jacobs Melanie Finnigan Shannon Puhalla Andrew Dodson Vera Martins Maggie Cheang Sophie Perry Chris Holcombe Nicholas C Turner Claire Swift Judith M Bliss Source Type: research

< em > AACR Cancer Progress Report 2021 < /em > : Discovery Science Driving Clinical Breakthroughs
Clin Cancer Res. 2021 Oct 13. doi: 10.1158/1078-0432.CCR-21-3367. Online ahead of print.NO ABSTRACTPMID:34645645 | DOI:10.1158/1078-0432.CCR-21-3367 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Rajarshi Sengupta Sayyed Kaleem Zaidi Source Type: research

Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer
Clin Cancer Res. 2021 Oct 13:clincanres.1650.2021. doi: 10.1158/1078-0432.CCR-21-1650. Online ahead of print.ABSTRACTPURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with RAS wild-type (RASwt), metastatic colorectal adenocarcinoma (mCRC).EXPERIMENTAL DESIGN: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with {greater than or equal to} one prior line of therapy for advanced disease. We analyzed baseline on-treatment tumor tissues for changes in the tumor microenvironment (TME), using flow cytometry and multispectral imm...
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Christos Fountzilas David L Bajor Sarbajit Mukherjee Joel Saltzman Agnieszka K Witkiewicz Orla Maguire Hans Minderman Ram Nambiar Hanna R Rosenheck Erik S Knudsen Jason B Muhitch Scott I Abrams Chong Wang Alan D Hutson Kristopher Attwood Karen A Hicks Jen Source Type: research

Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer
Conclusion: Our data demonstrate that an oHSV encoding a full-length human IgG1 anti-CD47 mAb, when used as a single agent or combined with another agent, is a promising approach for improving ovarian cancer treatment via enhancing innate immunity, as well as performing its known oncolytic function and modulation of immune cells.PMID:34645647 | DOI:10.1158/1078-0432.CCR-21-1248 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Lei Tian Bo Xu Kun-Yu Teng Mihae Song Zheng Zhu Yuqing Chen Jing Wang Jianying Zhang Mingye Feng Balveen Kaur Lorna Rodriguez-Rodriguez Michael A Caligiuri Jianhua Yu Source Type: research

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study
Conclusions: Adavosertib showed preliminary efficacy when combined with chemotherapy. The most promising treatment combination was adavosertib 225 mg twice daily on days 1-3, 8-10, and 15-17 plus carboplatin every 21 days. However, hematologic toxicity was more frequent than would be expected for carboplatin monotherapy, and the combination requires further study to optimize the dose, schedule, and supportive medications.PMID:34645648 | DOI:10.1158/1078-0432.CCR-21-0158 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Kathleen N Moore Setsuko K Chambers Erika P Hamilton Lee-May Chen Amit M Oza Sharad A Ghamande Gottfried E Konecny Steven C Plaxe Daniel L Spitz Jill J J Geenen Tiffany A Troso-Sandoval Janiel M Cragun Esteban Rodrigo Imedio Sanjeev Kumar Ganesh M Mugundu Source Type: research

Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer
Clin Cancer Res. 2021 Oct 13:clincanres.1628.2021. doi: 10.1158/1078-0432.CCR-21-1628. Online ahead of print.ABSTRACTPurpose: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2- breast cancer; (ii) the pharmacodynamic effect of the agents on the biomarkers. Experimental design: 307 postmenopausal women with ER+/HER2- primary breast cancer were randomly assigned to neoadjuvant treatment with letrozole for 14 weeks; letrozole for 2 weeks, then letrozole+palbociclib to 14 weeks; palbociclib for 2 weeks, then letroz...
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Mitch Dowsett Lucy Kilburn Mothaffar F Rimawi C Kent Osborne Katherine Pogue-Geile Yuan Liu Samuel A Jacobs Melanie Finnigan Shannon Puhalla Andrew Dodson Vera Martins Maggie Cheang Sophie Perry Chris Holcombe Nicholas C Turner Claire Swift Judith M Bliss Source Type: research

< em > AACR Cancer Progress Report 2021 < /em > : Discovery Science Driving Clinical Breakthroughs
Clin Cancer Res. 2021 Oct 13. doi: 10.1158/1078-0432.CCR-21-3367. Online ahead of print.NO ABSTRACTPMID:34645645 | DOI:10.1158/1078-0432.CCR-21-3367 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Rajarshi Sengupta Sayyed Kaleem Zaidi Source Type: research

Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer
Clin Cancer Res. 2021 Oct 13:clincanres.1650.2021. doi: 10.1158/1078-0432.CCR-21-1650. Online ahead of print.ABSTRACTPURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with RAS wild-type (RASwt), metastatic colorectal adenocarcinoma (mCRC).EXPERIMENTAL DESIGN: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with {greater than or equal to} one prior line of therapy for advanced disease. We analyzed baseline on-treatment tumor tissues for changes in the tumor microenvironment (TME), using flow cytometry and multispectral imm...
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Christos Fountzilas David L Bajor Sarbajit Mukherjee Joel Saltzman Agnieszka K Witkiewicz Orla Maguire Hans Minderman Ram Nambiar Hanna R Rosenheck Erik S Knudsen Jason B Muhitch Scott I Abrams Chong Wang Alan D Hutson Kristopher Attwood Karen A Hicks Jen Source Type: research

Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer
Conclusion: Our data demonstrate that an oHSV encoding a full-length human IgG1 anti-CD47 mAb, when used as a single agent or combined with another agent, is a promising approach for improving ovarian cancer treatment via enhancing innate immunity, as well as performing its known oncolytic function and modulation of immune cells.PMID:34645647 | DOI:10.1158/1078-0432.CCR-21-1248 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Lei Tian Bo Xu Kun-Yu Teng Mihae Song Zheng Zhu Yuqing Chen Jing Wang Jianying Zhang Mingye Feng Balveen Kaur Lorna Rodriguez-Rodriguez Michael A Caligiuri Jianhua Yu Source Type: research

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study
Conclusions: Adavosertib showed preliminary efficacy when combined with chemotherapy. The most promising treatment combination was adavosertib 225 mg twice daily on days 1-3, 8-10, and 15-17 plus carboplatin every 21 days. However, hematologic toxicity was more frequent than would be expected for carboplatin monotherapy, and the combination requires further study to optimize the dose, schedule, and supportive medications.PMID:34645648 | DOI:10.1158/1078-0432.CCR-21-0158 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Kathleen N Moore Setsuko K Chambers Erika P Hamilton Lee-May Chen Amit M Oza Sharad A Ghamande Gottfried E Konecny Steven C Plaxe Daniel L Spitz Jill J J Geenen Tiffany A Troso-Sandoval Janiel M Cragun Esteban Rodrigo Imedio Sanjeev Kumar Ganesh M Mugundu Source Type: research

Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer
Clin Cancer Res. 2021 Oct 13:clincanres.1628.2021. doi: 10.1158/1078-0432.CCR-21-1628. Online ahead of print.ABSTRACTPurpose: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2- breast cancer; (ii) the pharmacodynamic effect of the agents on the biomarkers. Experimental design: 307 postmenopausal women with ER+/HER2- primary breast cancer were randomly assigned to neoadjuvant treatment with letrozole for 14 weeks; letrozole for 2 weeks, then letrozole+palbociclib to 14 weeks; palbociclib for 2 weeks, then letroz...
Source: Clinical Cancer Research - October 14, 2021 Category: Cancer & Oncology Authors: Mitch Dowsett Lucy Kilburn Mothaffar F Rimawi C Kent Osborne Katherine Pogue-Geile Yuan Liu Samuel A Jacobs Melanie Finnigan Shannon Puhalla Andrew Dodson Vera Martins Maggie Cheang Sophie Perry Chris Holcombe Nicholas C Turner Claire Swift Judith M Bliss Source Type: research

Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences
Clin Cancer Res. 2021 Oct 8:clincanres.2404.2021. doi: 10.1158/1078-0432.CCR-21-2404. Online ahead of print.ABSTRACTPURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates.EXPERIMENTAL DESIGN: We recruited 168 stage III colorectal cancer pati...
Source: Clinical Cancer Research - October 9, 2021 Category: Cancer & Oncology Authors: Tenna Vesterman Henriksen Noelia Tarazona Amanda Frydendahl Thomas Reinert Francisco Gimeno-Valiente Juan Antonio Carbonell-Asins Shruti Sharma Derrick Renner Dina Hafez Desamparados Roda Marisol Huerta Susana Rosell ó Anders Husted Madsen Uffe S L øve Source Type: research

Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences
Clin Cancer Res. 2021 Oct 8:clincanres.2404.2021. doi: 10.1158/1078-0432.CCR-21-2404. Online ahead of print.ABSTRACTPURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates.EXPERIMENTAL DESIGN: We recruited 168 stage III colorectal cancer pati...
Source: Clinical Cancer Research - October 9, 2021 Category: Cancer & Oncology Authors: Tenna Vesterman Henriksen Noelia Tarazona Amanda Frydendahl Thomas Reinert Francisco Gimeno-Valiente Juan Antonio Carbonell-Asins Shruti Sharma Derrick Renner Dina Hafez Desamparados Roda Marisol Huerta Susana Rosell ó Anders Husted Madsen Uffe S L øve Source Type: research

Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences
Clin Cancer Res. 2021 Oct 8:clincanres.2404.2021. doi: 10.1158/1078-0432.CCR-21-2404. Online ahead of print.ABSTRACTPURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates.EXPERIMENTAL DESIGN: We recruited 168 stage III colorectal cancer pati...
Source: Clinical Cancer Research - October 9, 2021 Category: Cancer & Oncology Authors: Tenna Vesterman Henriksen Noelia Tarazona Amanda Frydendahl Thomas Reinert Francisco Gimeno-Valiente Juan Antonio Carbonell-Asins Shruti Sharma Derrick Renner Dina Hafez Desamparados Roda Marisol Huerta Susana Rosell ó Anders Husted Madsen Uffe S L øve Source Type: research

Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences
Clin Cancer Res. 2021 Oct 8:clincanres.2404.2021. doi: 10.1158/1078-0432.CCR-21-2404. Online ahead of print.ABSTRACTPURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates.EXPERIMENTAL DESIGN: We recruited 168 stage III colorectal cancer pati...
Source: Clinical Cancer Research - October 9, 2021 Category: Cancer & Oncology Authors: Tenna Vesterman Henriksen Noelia Tarazona Amanda Frydendahl Thomas Reinert Francisco Gimeno-Valiente Juan Antonio Carbonell-Asins Shruti Sharma Derrick Renner Dina Hafez Desamparados Roda Marisol Huerta Susana Rosell ó Anders Husted Madsen Uffe S L øve Source Type: research

Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
CONCLUSION: Altogether, we demonstrate the unique expression pattern of mucins, four mucins-based PDAC subtypes, and the contribution of MUC1, MUC4, and MUC16 SVs in PDAC patient survival.PMID:34615717 | DOI:10.1158/1078-0432.CCR-21-1591 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Christopher M Thompson Andrew Cannon Sean West Dario Ghersi Pranita Atri Rakesh Bhatia Lynette Smith Satyayanarayana Rachagani Christopher Wichman Sushil Kumar Surinder K Batra Source Type: research

Phase 1/2a trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors
CONCLUSIONS: BMS-986148 {plus minus} nivolumab demonstrated a clinically manageable safety profile and preliminary evidence of clinical activity, supporting additional studies combining directed cytotoxic therapies with checkpoint inhibitors as potential multimodal therapeutic strategies in patients with advanced solid tumors.PMID:34615718 | DOI:10.1158/1078-0432.CCR-21-1181 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Sylvie Rottey Jeffrey Clarke Kyaw Aung Jean-Pascal Machiels Ben Markman Kimberley M Heinhuis Michael Millward Martijn Lolkema Sandip Pravin Patel Paul de Souza Matteo Duca Giuseppe Curigliano Armando Santoro Takafumi Koyama Michelle Brown Heather Vezina C Source Type: research

A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer
CONCLUSIONS: Despite successful target engagement and anticipated pharmacokinetic profile, lacnotuzumab+gem-carbo showed comparable antitumor activity to gem-carbo alone, with slightly poorer tolerability. However, the data presented in this manuscript would be informative for future studies testing agents targeting the CSF-1-CSF-1R pathway in TNBC.PMID:34615719 | DOI:10.1158/1078-0432.CCR-20-3955 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Sherko Kuemmel Mario Campone Delphine Loirat Rafael L ópez López J Thaddeus Beck Michelino De Laurentiis Seock-Ah Im Sung-Bae Kim Ava Kwong Guenther G Steger Esther Zamora Adelantado Francois P Duhoux Richard Greil Irene Kuter Yen-Shen Lu Ariadna Tibau Source Type: research

Anti-PD1 efficacy in metastatic urothelial cancer patients associates with intra-tumoral juxtaposition of T helper-type 1 and CD8+ T-cells
CONCLUSIONS: A decrease in the fraction of circulating PD1+ CD4+ T-cells, and juxtaposition of Th1, CD8+, and myeloid cells was associated with response to anti-PD1 treatment in mUC patients.PMID:34615720 | DOI:10.1158/1078-0432.CCR-20-3319 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Maud Rijnders Hayri E Balcioglu Debbie G J Robbrecht Astrid A M Oostvogels Rebecca Wijers Maureen J B Aarts Paul Hamberg Geert J L H van Leenders J Alberto Nakauma-Gonz ález Jens Voortman Hans M Westgeest Joost L Boormans Ronald de Wit Martijn Lolkema As Source Type: research

Adjuvant imatinib in GIST patients harboring exon 9 KIT mutations: results from a multi-institutional European retrospective study
CONCLUSION: In this retrospective series of KIT exon 9-mutated GIST patients treated with adjuvant imatinib, a daily dose of 800 mg versus 400 mg did not show better results in terms of survival outcomes. Prospective evaluation of the more appropriate adjuvant treatment in this setting is warranted.PMID:34615721 | DOI:10.1158/1078-0432.CCR-21-1665 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Bruno Vincenzi Andrea Napolitano Marta Fiocco Olivier Mir Piotr Rutkowski Jean-Yves Blay Peter Reichardt Heikki Joensuu Elena Fumagalli Spyridon Gennatas Nadia Hindi Margherita Nannini Mariella Spalato Ceruso Antoine Italiano Giovanni Grignani Antonella B Source Type: research

Predictive significance of an optimized panel for basal-like breast cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 phase III clinical trials
CONCLUSIONS: The nestin/INPP4B immunohistochemical panel identifies women with basal breast cancers who benefit from non-anthracycline chemotherapy but not endocrine adjuvant treatments.PMID:34615722 | DOI:10.1158/1078-0432.CCR-21-1942 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Karama Asleh Dongsheng Tu Dongxia Gao Vivien Bramwell Mark N Levine Kathleen I Pritchard Lois E Shepherd Torsten O Nielsen Source Type: research

Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
CONCLUSIONS: BTK and pan-PI3K inhibition in mantle cell lymphoma demonstrates a promising efficacy signal. Addition of BCL2 inhibitors to a BTK and pan-PI3K combination remain suitable for further development in mantle cell lymphoma.PMID:34615723 | DOI:10.1158/1078-0432.CCR-21-2183 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Caitlin M Stewart Laure Michaud Karissa Whiting Reiko Nakajima Chelsea Nichols Stephanie De Frank Paul A Hamlin Matthew J Matasar John F Gerecitano Pamela Drullinsky Audrey Hamilton David Straus Steven M Horwitz Anita Kumar Craig H Moskowitz Alison Moskow Source Type: research

18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
CONCLUSIONS: The results generated from this work provide an immediately translatable paradigm for measuring and targeting hypoxia to increase response to immune checkpoint therapy and using hypoxia imaging to guide combinatory therapies.PMID:34615724 | DOI:10.1158/1078-0432.CCR-21-2394 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Kirsten M Reeves Patrick N Song Allyson Angermeier Deborah Della Manna Yufeng Li Jianbo Wang Eddy S Yang Anna G Sorace Benjamin M Larimer Source Type: research

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers
CONCLUSIONS: Ivuxolimab was generally well tolerated with on-target immune activation at clinically relevant doses, showed preliminary anti-tumor activity, and may serve as a partner for combination studies.PMID:34615725 | DOI:10.1158/1078-0432.CCR-21-0845 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Adi Diab Omid Hamid John A Thompson Willeke Ros Ferry A L M Eskens Toshihiko Doi Siwen Hu-Lieskovan Samuel J Klempner Bishu Ganguly Catherine Fleener Xiao Wang Tenshang Jo Ken Liao Shahram Salek-Ardakani Carrie Turich Taylor Jeffrey Chou Anthony B El-Khou Source Type: research